keyword
https://read.qxmd.com/read/38354747/the-relevance-of-integrating-cyp2c19-phenoconversion-effects-into-clinical-pharmacogenetics
#21
JOURNAL ARTICLE
Maike Scherf-Clavel, Heike Weber, Stefan Unterecker, Amelie Frantz, Andreas Eckert, Andreas Reif, Jürgen Deckert, Martina Hahn
INTRODUCTION: CYP2D6 and CYP2C19 functional status as defined by genotype is modulated by phenoconversion (PC) due to pharmacokinetic interactions. As of today, there is no data on the effect size of PC for CYP2C19 functional status. The primary aim of this study was to investigate the impact of PC on CYP2C19 functional status. METHODS: Two patient cohorts (total n=316; 44.2±15.4 years) were investigated for the functional enzyme status of CYP2C19 applying two different correction methods (PCBousman , PCHahn&Roll ) as well as serum concentration and metabolite-to-parent ratio of venlafaxine, amitriptyline, mirtazapine, sertraline, escitalopram, risperidone, and quetiapine...
February 14, 2024: Pharmacopsychiatry
https://read.qxmd.com/read/38345252/comparative-efficacy-of-p-cabs-versus-proton-pump-inhibitors-for-grade-c-d-esophagitis-a-systematic-review-and-network-meta-analysis
#22
JOURNAL ARTICLE
Qianjun Zhuang, Songfeng Chen, Xuyu Zhou, Xingyu Jia, Mengyu Zhang, Niandi Tan, Fangfei Chen, Zhanye Zhang, Junnan Hu, Yinglian Xiao
BACKGROUND: s and Aims: Los Angeles (LA) grade C/D esophagitis is a severe manifestation of GERD that require active treatment and close follow-up. Potassium competitive acid blockers (P-CABs) are promising alternatives to proton-pump inhibitors (PPIs). We aimed to compare the efficacy and safety of P-CABs and PPIs in healing Grade C/D esophagitis to aid clinical decision-making. METHODS: A systematic literature search was performed using PubMed, MEDLINE, Cochrane Central Register of Controlled Trials...
February 12, 2024: American Journal of Gastroenterology
https://read.qxmd.com/read/38332683/eradication-rate-and-adherence-with-high-dose-amoxicillin-and-proton-pump-inhibitor-as-first-line-treatment-for-helicobacter-pylori-infection-experience-from-university-hospital-in-chile
#23
JOURNAL ARTICLE
Christian von Muhlenbrock, Andrea Cordova, Paulina Nuñez, Nicole Pacheco, Karin Herrera, Rodrigo Quera
INTRODUCTION: In Chile, more than 70% of adults are infected by Helicobacter pylori. Clarithromycin should not be used in any regimen if there is >15% resistance to this antibiotic, being greater than 26% in our population. In this scenario, the effectiveness of triple therapy (proton pump inhibitor [PPI], clarithromycin, amoxicillin) was only 63.8%. AIM: To evaluate the eradication rate and safety of dual therapy (esomeprazole and amoxicillin) in high doses, through a prospective, observational, and descriptive study...
2024: Helicobacter
https://read.qxmd.com/read/38323705/tailored-therapy-guided-by-genotypic-resistance-of-clarithromycin-and-levofloxacin-detected-by-polymerase-chain-reaction-in-the-first-line-treatment-of-helicobacter-pylori-infection
#24
JOURNAL ARTICLE
Cai Ling Li, Kai Zhou, Yue Xi Zhang, Bao Jun Suo, Xue Li Tian, Yu Xin Zhang, Xin Lu Ren, Yan Yan Shi, Li Ya Zhou, Zhi Qiang Song
OBJECTIVES: We aimed to explore the efficacy and safety of tailored therapy guided by genotypic resistance in the first-line treatment of Helicobacter pylori (H. pylori) infection in treatment-naive patients. METHODS: Gastric mucosal specimens were taken during gastroscopy, and main mutations of clarithromycin- and levofloxacin-resistant genes were detected by polymerase chain reaction (PCR). Sensitive antibiotics were selected individually for treating H. pylori infection with tailored bismuth-containing quadruple therapy (BQT) consisting of esomeprazole 20 mg twice daily, bismuth potassium citrate 220 mg twice daily, amoxicillin 1 g twice daily, and clarithromycin 500 mg twice daily, or levofloxacin 500 mg once daily, or metronidazole 400 mg four times daily...
February 7, 2024: Journal of Digestive Diseases
https://read.qxmd.com/read/38258325/relationships-of-proton-pump-inhibitor-induced-renal-injury-with-cyp2c19-polymorphism-a-retrospective-cohort-study
#25
JOURNAL ARTICLE
Rika Fukui, Satoshi Noda, Yoshito Ikeda, Yuichi Sawayama, Tomohiro Terada, Yoshihisa Nakagawa, Shin-Ya Morita
Proton pump inhibitors (PPIs) have recently been reported to be linked with nephrotoxicity. PPIs are metabolized mainly or partly by cytochrome P450 2C19 (CYP2C19). However, the relationship between CYP2C19 genetic polymorphism and PPI-induced nephrotoxicity is unclear. In this study, we aimed to analyze the association between the time of occurrence of renal injury by PPIs, including lansoprazole, esomeprazole, rabeprazole, and vonoprazan, and CYP2C19 metabolizer status classified by CYP2C19 genotypes. Patients prescribed PPIs were reviewed in this retrospective cohort study...
January 22, 2024: Clinical Pharmacology and Therapeutics
https://read.qxmd.com/read/38251791/the-efficacy-and-safety-of-fexuprazan-in-treating-erosive-esophagitis-a-phase-iii-randomized-double-blind-multicenter-study
#26
JOURNAL ARTICLE
Qianjun Zhuang, Aijun Liao, Qingling He, Chengxia Liu, Changqing Zheng, Xing Li, Youli Liu, Bangmao Wang, Side Liu, Yan Zhang, Rong Lin, Huixin Chen, Min Deng, Yanping Tang, Chiyi He, Weijie Dai, Haitao Tang, Lei Gong, Liangping Li, Baohong Xu, Changqing Yang, Bingxi Zhou, Dongxing Su, Qinghong Guo, Bin Li, Yongjian Zhou, Xiaoyang Wang, Sujuan Fei, Huili Wu, Sichen Wei, Zhihong Peng, Jianning Wang, Yanqing Li, Hong Wang, Tianwei Deng, Shigang Ding, Fangfang Li, Minhu Chen, Yinglian Xiao
BACKGROUND AND AIM: Fexuprazan is a novel potassium-competitive acid blocker (P-CAB). This study aimed to explore the noninferior efficacy and safety of fexuprazan to esomeprazole in treating erosive esophagitis (EE). METHODS: This was a phase III, randomized, double-blind multicenter study. Patients with endoscopically confirmed EE were randomized to receive fexuprazan 40 mg or esomeprazole 40 mg once a daily for 4-8 weeks. The healing rates of EE, symptom response, GERD-health-related quality life (GERD-HRQL), and treatment-emergent adverse events (TEAEs) were compared between fexuprazan group and esomeprazole group...
January 22, 2024: Journal of Gastroenterology and Hepatology
https://read.qxmd.com/read/38242960/gastroprotective-effect-of-rhodanine-and-2-4-thiazolidinediones-scaffolds-in-rat-stomachs-by-contribution-of-anti-apoptotic-bcl-2-and-tumor-suppressor-p53-proteins
#27
JOURNAL ARTICLE
Rozh Q Ameen, Zahra A Amin, Hiwa O Ahmad, Diler D Ghafur, Melodya G Toma, Nyan Sabah, Muhammad Fakhir, Gardoon Abdulla
In recent times, the methods used to evaluate gastric ulcer healing worldwide have been based on visual examinations and estimating ulcer dimensions in experimental animals. In this study, the protective effect of rhodanine and 2,4-thiazolidinediones scaffolds compared to esomeprazole was investigated in an ethanol model of stomach ulcers in rats. Pretreatment with experimental treatments or esomeprazole prevented the development of ethanol-induced gastric ulcers. The severity of the lesions and injuries was significantly lower than that of vehicle (10% Tween 80) treated rats...
January 19, 2024: Scientific Reports
https://read.qxmd.com/read/38231298/trend-analysis-of-proton-pump-inhibitor-consumption-and-expenditure-the-real-world-evidence
#28
JOURNAL ARTICLE
Francesco Ferrara, Maurizio Capuozzo, Venere Celotto, Alessandro Ottaiano, Roberto Langella, Andrea Zovi
INTRODUCTION: Proton pump inhibitors (PPIs) constitute a widely utilized pharmaceutical class, frequently associated with notable instances of therapeutic inappropriateness. Such patterns of misuse not only contribute to elevated healthcare expenditure, but may also exacerbate clinical conditions in certain patients. METHODS: A comprehensive analysis was conducted between 2019 and 2023 to assess all prescriptions dispensed using the Anatomical, Therapeutic and Chemical (ATC) classification system, which allowed trends among primary PPIs to be visualized...
January 17, 2024: Indian Journal of Gastroenterology: Official Journal of the Indian Society of Gastroenterology
https://read.qxmd.com/read/38225650/efficacy-of-a-2-week-therapy-with-levofloxacin-concomitant-versus-a-levofloxacin-sequential-regimen-for-helicobacter-pylori-infection-in-the-syrian-population-a-study-protocol-for-randomized-controlled-trial
#29
JOURNAL ARTICLE
Marouf Alhalabi, Rasha Almokdad
BACKGROUND: Treating Helicobacter pylori is becoming increasingly difficult with the development of bacterial resistance to many established treatment regimens. As a result, researchers are constantly looking for novel and effective treatments. This trial aims to establish the efficacy of levofloxacin-based sequential treatment regimen and concomitant levofloxacin-based regimen as empirical first-line therapy in the Syrian population. METHOD: This is an open-label, prospective, single-center, parallel, active-controlled, superiority, randomized clinical trial...
January 15, 2024: Trials
https://read.qxmd.com/read/38213955/omeprazole-induced-rapid-drug-reaction-with-eosinophilia-systemic-symptoms-and-cross-reactivity-in-delayed-type-hypersensitivity-associated-with-proton-pump-inhibitors-a-case-report-and-literature-review
#30
Kanokkarn Pinyopornpanish, Kanokporn Pinyopornpanish, Kanokwan Pinyopornpanish, Juthipong Benjanuwattra, Putthapon Teepapan, Apinya Chungcharoenpanich, Wannada Laisuan
BACKGROUND: Omeprazole, a proton pump inhibitor (PPI), is a widely used and generally safe agent for treating acid-related gastrointestinal conditions. However, drug reaction with eosinophilia and systemic symptoms (DRESSs) syndrome has been reported. OBJECTIVES: To report a case of omeprazole-induced rapid DRESS syndrome and to review the literature. METHODS: Descriptive analysis of one new case and a case series from literature review. RESULTS: We report a case of 82-year-old woman presenting with rapid-onset of DRESS syndrome...
2024: Case Reports in Immunology
https://read.qxmd.com/read/38205049/the-impact-of-nutrition-on-the-onset-course-of-disease-and-quality-of-life-of-patients-with-laryngopharyngeal-reflux
#31
JOURNAL ARTICLE
Tin Prpić, Melita Peček Prpić, Tihana Mendeš, Anamarija Šestak, Andrijana Včeva
RESEARCH BACKGROUND: The role of dietary habits of patients with laryngopharyngeal reflux (LPR) is comparatively underexplored. The aim of the study is to examine dietary habits, onset and course of the disease as well as the quality of life of patients with LPR. EXPERIMENTAL APPROACH: The results of the modified food frequency questionnaire (FFQ-m) and laryngopharyngeal reflux health-related quality of life (LPR-HRQL) questionnaires were compared between subjects with and without LPR...
December 2023: Food Technology and Biotechnology
https://read.qxmd.com/read/38200764/successful-emergency-management-of-a-dog-with-ventilator-dependent-acquired-myasthenia-gravis-with-immunoadsorption
#32
Florian Sänger, Stefanie Dörfelt, Bettina Giani, Gesine Buhmann, Andrea Fischer, René Dörfelt
A one-year-old, female intact Samoyed, 12.5 kg, was presented with coughing for 2 weeks, progressive appendicular and axial muscle weakness, megaesophagus and labored breathing for 5 days. There was no improvement with standard treatment. Acquired myasthenia gravis was suspected and the dog was referred with increasing dyspnea. At presentation, the dog showed a severely reduced general condition, was non-ambulatory and showed abdominal and severely labored breathing. A marked hypercapnia (PvCO2 = 90.1 mmHg) was present in venous blood gas analysis...
December 21, 2023: Animals: An Open Access Journal From MDPI
https://read.qxmd.com/read/38197874/clinical-study-on-the-eradication-of-helicobacter-pylori-by-vonoprazan-combined-with-amoxicillin-for-10-day-dual-therapy
#33
JOURNAL ARTICLE
Kunfeng Yan, Xiaorong Dai, Zhenxing Li, Weiwei Rong, Lei Chen, Xinxin Diao
Vonoprazan holds significant research promise for Helicobacter pylori eradication, with the goal of determining the most effective drug regimen. In this study, H. pylori patients (426) were enrolled and randomized into 3 groups: an EA14 group (20 mg of esomeprazole qid and 1000 mg of amoxicillin tid for 14 days), a VA14 group (20 mg of vonoprazan bid and 750 mg of amoxicillin qid for 14 days), and a VA10 group (20 mg of vonoprazan bid and 1000 mg of amoxicillin tid for 10 days)...
January 10, 2024: Clinical Pharmacology in Drug Development
https://read.qxmd.com/read/38142444/prescribing-patterns-of-proton-pump-inhibitors-in-germany-a-retrospective-study-including-472%C3%A2-146-patients
#34
JOURNAL ARTICLE
Kate Plehhova, Monika Haering, Joshua Wray, Cathal Coyle, Eduardo Ibáñez, Karel Kostev
The aims of this study were to analyze proton pump inhibitor (PPI) users in Germany, defining and classifying them in terms of treatment appropriateness, and to analyze the PPI prescription practices of healthcare providers. The updated DGVS (Deutsche Gesellschaft für Gastroenterologie, Verdauungs-und Stoffwechselkrankheiten) gastroesophageal reflux disease (GERD) treatment guideline (published March 2023) for mild heartburn symptoms recommends carrying out a probatory treatment of mild symptoms via other medication such as antacids, alginates, and H2 blockers before escalating to PPI treatments, if the patient profile allows...
2023: Journal of Primary Care & Community Health
https://read.qxmd.com/read/38133593/vonoprazan-voquezna-for-erosive-esophagitis
#35
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
December 25, 2023: Medical Letter on Drugs and Therapeutics
https://read.qxmd.com/read/38110901/efficacy-and-safety-of-hip1601-dual-delayed-release-esomeprazole-40%C3%A2-mg-in-erosive-esophagitis-compared-to-hgp1705-delayed-release-esomeprazole-40%C3%A2-mg-a-multicenter-randomized-double-blind-non-inferiority-study
#36
RANDOMIZED CONTROLLED TRIAL
Hyun Lim, Jong Kyu Park, Hyunsoo Chung, Si Hyung Lee, Jae Myung Park, Jung Ho Park, Gwang Ha Kim, Sung Kwan Shin, Su Jin Hong, Kwang Jae Lee, Moo In Park, Hye-Kyung Jung, Hyun-Soo Kim, Jae Kyu Sung, Seong Woo Jeon, Suck Chei Choi, Jeong Seop Moon, Nayoung Kim, Jong-Jae Park, Sung Hee Hong, Na Young Kim, Hwoon-Yong Jung
BACKGROUND: Proton-pump inhibitors (PPIs) are the most effective drugs for treating acid-related disorders. However, once-daily dosing with conventional PPIs fail to fully control acid secretion over 24 h. This study aimed to compare the efficacy and safety of HIP1601 (dual delayed-release esomeprazole) and HGP1705 (delayed-release esomeprazole) in patients with erosive esophagitis (EE). METHODS: We enrolled 213 patients with EE randomized in a 1:1 ratio to receive 40 mg HIP1601 (n = 107) or HGP1705 (n = 106) once daily for 4 or 8 weeks...
December 18, 2023: BMC Gastroenterology
https://read.qxmd.com/read/38049205/acid-suppressive-drugs-a-systematic-review-and-network-meta-analysis-of-their-nocturnal-acid-inhibitory-effect
#37
JOURNAL ARTICLE
Shupeng Zou, Mengling Ouyang, Qian Cheng, Xuan Shi, Minghui Sun
BACKGROUND AND AIMS: Acid-suppressive drugs (ASDs) are widely used in many gastric acid-associated diseases. Nocturnal acid breakthrough has been a common problem of many ASDs, such as proton-pump inhibitors (PPIs) and H2 -receptor antagonists (H2RAs). Potassium-competitive acid blockers (P-CABs) are expected to solve this continuing conundrum. This article examined major ASDs and compared them with placebo in terms of nocturnal acid-inhibitory effects, using a network meta-analysis of randomized controlled trials (RCTs)...
December 4, 2023: Pharmacotherapy
https://read.qxmd.com/read/38039033/assessing-the-hypolipidemic-and-gastro-liver-protective-activity-of-herbal-combination-with-emphasis-on-ppi-amid-selected-multiple-antihypertensive-drug-combination-in-experimental-animal-models
#38
JOURNAL ARTICLE
R P Monisa, A K Azad, I Rahma, J T Israt, A Shopnil, A K Ayaz, U H Taqweem, T Aziz, A Metab, H A Thamer, F A Abdullah
OBJECTIVE: Peptic ulcer (PU) and hypertension are chronic diseases affecting up to 10% and 30% of the adult population worldwide. Most of these patients will require treatment with a combination of antihypertensive medicines, which have adverse effects on the body's different organs. This study specifically focused on antihypertensive multi-drug induced PU disease and disturbance of liver function. MATERIALS AND METHODS: During a 14-day oral administration of antihypertensive drugs, Cilnidipine (1 mg/kg), Rosuvastatin (1 mg/kg), Bisoprolol (0...
November 2023: European Review for Medical and Pharmacological Sciences
https://read.qxmd.com/read/38006986/investigation-into-the-impact-of-proton-pump-inhibitors-on-sertraline-transport-across-the-blood-brain-barrier
#39
JOURNAL ARTICLE
Yumeng Xiao, Wenwen Xu, Dandan Niu, Zhuowei Quan, Ling Wang
As a widely used antidepressant that works by inhibiting the reuptake of serotonin, sertraline exerts an antidepressant effect depending on its concentration in the brain, which might be limited by the blood-brain barrier (BBB). It is highly possible to combine proton pump inhibitors (PPIs) with sertraline in clinical trials. Nevertheless, the role played by PPIs in regulating the transport of sertraline across the BBB remains unclear. Here, the impact of PPIs on the distribution of sertraline in the brain and the mechanisms involved were investigated...
November 23, 2023: European Journal of Pharmaceutical Sciences
https://read.qxmd.com/read/38004576/oral-drug-absorption-and-drug-disposition-in-critically-ill-cardiac-patients
#40
JOURNAL ARTICLE
Lars-Olav Harnisch, Jürgen Brockmöller, Anne Hapke, Juliane Sindern, Ellen Bruns, Ruben Evertz, Karl Toischer, Bernhard C Danner, Dorothee Mielke, Veit Rohde, Tammam Abboud
(1) Background: In critically ill cardiac patients, parenteral and enteral food and drug administration routes may be used. However, it is not well known how drug absorption and metabolism are altered in this group of adult patients. Here, we analyze drug absorption and metabolism in patients after cardiogenic shock using the pharmacokinetics of therapeutically indicated esomeprazole. (2) Methods: The pharmacokinetics of esomeprazole were analyzed in a consecutive series of patients with cardiogenic shock and controls before and after elective cardiac surgery...
November 7, 2023: Pharmaceutics
keyword
keyword
3616
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.